<DOC>
	<DOCNO>NCT02549430</DOCNO>
	<brief_summary>This study aim assess activity PD0332991 monotherapy combination endocrine therapy ( anastrozole , letrozole , exemestane fulvestrant ) patient progress previous line advance breast cancer order reverse endocrine resistance .</brief_summary>
	<brief_title>To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy v PD 0332991 Combination With Endocrine Therapy</brief_title>
	<detailed_description>In clinical context , lack molecular compound demonstrate clinical activity delaying/reversing resistance endocrine agent . CDK 4/6 inhibitor may represent biologically-driven option context . With present study investigator aim complement ongoing trial PD0332991 acquire information clinical activity post-menopausal patient ER positive , Her2 negative advance breast cancer patient already pretreated first-line second line endocrine therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Histologically proven diagnosis adenocarcinoma breast evidence metastatic disease ER positive tumor â‰¥ 10 % HER2 negative breast cancer FISH IHC Progression advance breast cancer first second line endocrine therapy advance breast cancer Paraffinembedded tumor available centralized assessment biomarkers Measurable disease accord RECIST 1.1 ( bone disease allow measurable ) . Postmenopausal status Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 2 Resolution acute toxic effect prior therapy surgical procedure CTCAE grade &gt; 1 Adequate organ function Unstable brain metastasis Prior treatment one line CT two line HT advance breast cancer CDK inhibitor Current treatment therapeutic dos anticoagulant Current use anticipate need food drug know strong CYP3A4 inhibitor / inducer , drug predominantly metabolize CYP3A narrow therapeutic index , drug potential prolonging QT interval Diagnosis secondary malignancy within last 3 year Active inflammatory bowel disease chronic diarrhea Known human immunodeficiency virus infection ; active hepatitis C , active hepatitis B</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>ER positive</keyword>
	<keyword>Her2 negative</keyword>
</DOC>